CROI (Conference on Retroviruses and Opportunistic Infections)

The Latest

VRC01 in HIV-Exposed Newborns: First Results Support Monthly Injections for Those at Risk Through Breastfeeding

Preliminary results suggest that VRC01 -- an investigational HIV neutralising monoclonal antibody -- administered subcutaneously to neonates is safe and well tolerated.

By Polly Clayden for HIV i-Base

Raltegravir Pharmacokinetic Targets Met in High-Risk HIV-Exposed Infants

Daily raltegravir was safe and well tolerated at six weeks of life and met pharmacokinetic targets in HIV-exposed infants, according to data presented at CROI 2017.

By Polly Clayden for HIV i-Base

Tenofovir Alafenamide Exposure Is Modestly Higher in Children Than Adults

Tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) exposures are slightly higher in children aged 6-12 years compared with adults.

By Polly Clayden for HIV i-Base

World Health Organization Pediatric Dosing Tool

A pediatric dosing tool developed by the World Health Organization might assist in the design of clinical trials for dosing in children.

By Polly Clayden for HIV i-Base

Pre-ART Drug Resistance in Rural South Africa but Limited Clinical Impact With Good Adherence

The prevalence of transmitted drug resistance is above the WHO threshold of 5% in this study conducted in rural South Africa.

By Polly Clayden for HIV i-Base

Immune-Based Therapy Canakinumab Reduces Inflammatory Markers in HIV-Positive People on ART

"We believe this is one of the first immune-based therapies to show a very profound reduction in inflammatory markers in the setting of treated HIV," Priscilla Hsue, M.D. states.

By Richard Jefferys for HIV i-Base

CROI 2017: A View from My Seat at the Table

"At CROI, the 'executive director hat' comes off, and I'm purely a community advocate again," Rob Newells writes. "This year, that was even more true than in previous years."

By Rob Newells for AVAC: Global Advocacy for HIV Prevention

Bictegravir in the Body -- Preliminary Information About Drug Interactions

The experimental integrase inhibitor being developed by Gilead Sciences is currently in phase III clinical trials.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

A New Nuke in the Works -- GS-9131

The new nucleoside analogue GS-9131 may be useful as part of regimens for people who have strains of drug-resistant HIV.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

New Drugs, New Hope and Possible Timelines

At the recent Conference on Retroviruses and Opportunistic Infections, researchers presented data about 5 new anti-HIV compounds in development.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange